Advances in genome editing using “DNA scissors” such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) help to more quickly discover and produce new therapeutic options for conditions that are difficult to treat. Researchers are working, for example, to identify genes that are associated with cancer. The vision is to disable or change the specific genes using DNA scissors.
We want to equip researchers and scientists with the necessary solutions to develop new approaches for better healthcare. For faster drug discovery and for the biopharmaceutical production of genetically modified cell therapies, Merck produces innovative tools for genome editing and customized cell lines. This primarily includes functional genetic reagents and CRISPR libraries to screen genes and to knock out gene functions.
For over 14 years, our company has been active in the field of genome editing and strives to meet the growing need for genetically based therapeutics by continuously developing groundbreaking technologies. Our latest method “proxy-CRISPR
”, which is now being introduced to the market, makes genome editing even more efficient, more flexible and more specific, enabling access to genomic regions that have so far been unreachable using conventional tools.